Citadel Advisors
HCAT icon

Citadel Advisors’s Health Catalyst HCAT Stock Holding History

Citadel Advisors’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902K Buy
+453,214
New +$654K ﹤0.01% 8455
2025
Q3 		– Sell
-57,426
Closed -$216K – 13315
2025
Q2 		$216K Sell
57,426
-104,815
-65% -$412K ﹤0.01% 10511
2025
Q1 		$735K Sell
162,241
-122,687
-43% -$649K ﹤0.01% 7632
2024
Q4 		$2.01M Buy
284,928
+109,237
+62% +$870K ﹤0.01% 5607
2024
Q3 		$1.43M Buy
175,691
+16,399
+10% +$119K ﹤0.01% 6151
2024
Q2 		$1.02M Sell
159,292
-48,797
-23% -$313K ﹤0.01% 6541
2024
Q1 		$1.57M Sell
208,089
-33,619
-14% -$307K ﹤0.01% 6007
2023
Q4 		$2.24M Buy
241,708
+161,124
+200% +$1.32M ﹤0.01% 5164
2023
Q3 		$816K Buy
80,584
+66,681
+480% +$796K ﹤0.01% 7000
2023
Q2 		$174K Sell
13,903
-458,744
-97% -$5.46M ﹤0.01% 10103
2023
Q1 		$5.52M Sell
472,647
-389,814
-45% -$4.97M ﹤0.01% 3647
2022
Q4 		$9.17M Sell
862,461
-123,976
-13% -$1.2M ﹤0.01% 2961
2022
Q3 		$9.57M Buy
986,437
+132,866
+16% +$1.76M ﹤0.01% 2838
2022
Q2 		$12.4M Buy
853,571
+380,036
+80% +$6.48M ﹤0.01% 2407
2022
Q1 		$12.4M Buy
473,535
+454,723
+2,417% +$12.9M ﹤0.01% 2638
2021
Q4 		$746K Sell
18,812
-15,396
-45% -$702K ﹤0.01% 8670
2021
Q3 		$1.71M Sell
34,208
-37,139
-52% -$2.03M ﹤0.01% 6763
2021
Q2 		$3.96M Sell
71,347
-24,867
-26% -$1.32M ﹤0.01% 4959
2021
Q1 		$4.5M Sell
96,214
-106,209
-52% -$5.14M ﹤0.01% 4487
2020
Q4 		$8.81M Buy
202,423
+19,335
+11% +$713K ﹤0.01% 2823
2020
Q3 		$6.7M Buy
183,088
+172,501
+1,629% +$5.86M ﹤0.01% 2754
2020
Q2 		$309K Buy
10,587
+1,764
+20% +$48.7K ﹤0.01% 7861
2020
Q1 		$230K Buy
+8,823
New +$270K ﹤0.01% 7767
2019
Q4 		– Sell
-56,687
Closed -$1.79M – 9361
2019
Q3 		$1.79M Buy
+56,687
New +$2.23M ﹤0.01% 4655

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's HCAT Position: Q2 2026 in Review

Citadel Advisors opened a new position in Health Catalyst (HCAT) in Q2 2026: 453,214 shares worth $902K. The stake represents ﹤0.01% of the portfolio and ranks #8455 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HCAT as recently as Q2 2025.

Citadel Advisors first reported a position in HCAT in Q3 2019 and has held it in 24 quarters since. The position peaked at $12.4M in Q1 2022. 127 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Citadel Advisors held 453,214 shares of Health Catalyst worth $902K as of Q2 2026.
  • Health Catalyst was a new Citadel Advisors position in Q2 2026.
  • Health Catalyst made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8455 holding.
  • Citadel Advisors first reported a position in Health Catalyst in Q3 2019 and has held it in 24 quarters since.
  • Citadel Advisors's Health Catalyst position peaked at $12.4M in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.